| APABETALONE | Small molecule | pulmonary arterial hypertension | Bromodomain and extra-terminal motif (BET) inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| RO-6870810 | Small molecule | myelodysplastic syndrome | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| BIRABRESIB | Small molecule | prostate cancer | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| BIRABRESIB | Small molecule | NUT midline carcinoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Terminated | ClinicalTrials |
| BMS-986158 | Small molecule | myelofibrosis | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BIRABRESIB | Small molecule | breast cancer | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Terminated | ClinicalTrials |
| PELABRESIB | Small molecule | myelofibrosis | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Recruiting | ClinicalTrials |
| APABETALONE | Small molecule | coronary artery disease | Bromodomain and extra-terminal motif (BET) inhibitor | 2.0 | Completed | ClinicalTrials |
| PELABRESIB | Small molecule | tumour of cranial and spinal nerves | Bromodomain and extra-terminal motif (BET) inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BIRABRESIB | Small molecule | acute myeloid leukemia | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| BIRABRESIB | Small molecule | pancreatic ductal adenocarcinoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| APABETALONE | Small molecule | COVID-19 | Bromodomain and extra-terminal motif (BET) inhibitor | 2.0 | Recruiting | ClinicalTrials |
| MOLIBRESIB | Small molecule | neoplasm | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Terminated | ClinicalTrials |
| RO-6870810 | Small molecule | multiple myeloma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| APABETALONE | Small molecule | coronary artery disease | Bromodomain and extra-terminal motif (BET) inhibitor | 3.0 | Completed | ClinicalTrials |
| BIRABRESIB | Small molecule | glioblastoma multiforme | Bromodomain and extra-terminal motif (BET) inhibitor | 2.0 | Terminated | ClinicalTrials |
| APABETALONE | Small molecule | Fabry disease | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Unknown status | ClinicalTrials |
| BIRABRESIB | Small molecule | NUT midline carcinoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| BIRABRESIB | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Terminated | ClinicalTrials |
| PELABRESIB | Small molecule | lymphoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| RO-6870810 | Small molecule | acute myeloid leukemia | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| MOLIBRESIB | Small molecule | neoplasm | Bromodomain and extra-terminal motif (BET) inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| BIRABRESIB | Small molecule | prostate cancer | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Terminated | ClinicalTrials |
| BIRABRESIB | Small molecule | non-small cell lung carcinoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Terminated | ClinicalTrials |
| BIRABRESIB | Small molecule | diffuse large B-cell lymphoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Terminated | ClinicalTrials |
| BIRABRESIB | Small molecule | non-small cell lung carcinoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| APABETALONE | Small molecule | pulmonary arterial hypertension | Bromodomain and extra-terminal motif (BET) inhibitor | 0.5 | Completed | ClinicalTrials |
| RO-6870810 | Small molecule | high grade B-cell lymphoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| MOLIBRESIB | Small molecule | carcinoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| BMS-986158 | Small molecule | neoplasm | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| RO-6870810 | Small molecule | neoplasm | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| MOLIBRESIB | Small molecule | neoplasm | Bromodomain and extra-terminal motif (BET) inhibitor | 2.0 | Completed | ClinicalTrials |
| BMS-986158 | Small molecule | lymphoma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Recruiting | ClinicalTrials |
| BMS-986158 | Small molecule | multiple myeloma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Recruiting | ClinicalTrials |
| MOLIBRESIB | Small molecule | neoplasm | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| APABETALONE | Small molecule | chronic kidney disease | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Unknown status | ClinicalTrials |
| PELABRESIB | Small molecule | multiple myeloma | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |
| APABETALONE | Small molecule | diabetes mellitus | Bromodomain and extra-terminal motif (BET) inhibitor | 2.0 | Completed | ClinicalTrials |
| BIRABRESIB | Small molecule | breast cancer | Bromodomain and extra-terminal motif (BET) inhibitor | 1.0 | Completed | ClinicalTrials |